PMID- 38114205
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20231221
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 48
IP  - 22
DP  - 2023 Nov
TI  - [Research progress in mechanism of puerarin in treating vascular dementia].
PG  - 5993-6002
LID - 10.19540/j.cnki.cjcmm.20230718.401 [doi]
AB  - Vascular dementia(VD) is a condition of cognitive impairment due to acute and 
      chronic cerebral hypoperfusion. The available therapies for VD mainly focus on 
      mitigating cerebral ischemia, improving cognitive function, and controlling 
      mental behavior. Achievements have been made in the basic and clinical research 
      on the treatment of VD with traditional Chinese medicine(TCM) active components, 
      including Ginkgo leaf extract, puerarin, epimedium, tanshinone, and ginsenoside. 
      Most of these components have anti-inflammatory, anti-apoptotic, anti-oxidant, 
      and neuroprotective effects, and puerarin demonstrates excellent performance in 
      mitigating cholinergic nervous system disorders and improving synaptic 
      plasticity. Puerarin, ginkgetin, and epimedium are all flavonoids, while 
      tanshinone is a diterpenoid. Puerariae Lobatae Radix, pungent in nature, can 
      induce clear Yang to reach the cerebral orifices and has the wind medicine 
      functions of ascending, dispersing, moving, and scurrying. Puerariae Lobatae 
      Radix entering collaterals will dredge blood vessels to promote blood flow, and 
      that entering the sweat pore will open the mind, which is in line with the TCM 
      pathogenesis characteristics of VD. This study reviews the progress in the 
      mechanism of puerarin, the main active component of Puerariae Lobatae Radix, in 
      treating VD. Puerarin can ameliorate cholinergic nervous system disorders, reduce 
      excitotoxicity, anti-inflammation, inhibit apoptosis, alleviate oxidative stress 
      injury, enhance synaptic plasticity, up-regulate neuroprotective factor 
      expression, promote cerebral circulation metabolism, and mitigate Abeta injury. The 
      pathways of action include activating nuclear factor erythroid 2-related factor 
      2(Nrf2)/antioxidant response element(ARE), vascular endothelial growth 
      factor(VEGF), extracellular regulated protein kinases(ERK), 
      phosphatidylinositol-3-kinase(PI3K)/protein kinase B(Akt), Janus-activating 
      kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3), 
      AMP-activated protein kinase(AMPK), as well as inhibiting the tumor necrosis 
      factor alpha(TNF-alpha), transient receptor potential melastatin 
      2(TRPM2)/N-methyl-D-aspartate receptor(NMDAR), p38 mitogen-activated protein 
      kinase(p38 MAPK), Toll-like receptor 4(TLR4)/nuclear factor-kappaB(NF-kappaB), early 
      growth response 1(Egr-1), and matrix metalloproteinase 9(MMP-9). By reviewing the 
      papers about the treatment of VD by puerarin published by CNKI, Wanfang, VIP, 
      PubMed, and Web of Science in the last 10 years, this study aims to support the 
      treatment and drug development for VD.
FAU - Qi, Da-He
AU  - Qi DH
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Ma, Hua
AU  - Ma H
AD  - Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, 
      China.
FAU - Chen, Yuan-Yuan
AU  - Chen YY
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Wang, Ke-Xin
AU  - Wang KX
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Ding, Meng-Meng
AU  - Ding MM
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Hao, Yun-Long
AU  - Hao YL
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Guo, Ye
AU  - Guo Y
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
FAU - Kong, Ling-Bo
AU  - Kong LB
AD  - Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 
      100700, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 03UUH3J385 (tanshinone)
RN  - Z9W8997416 (puerarin)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (NF-kappa B)
RN  - 0 (Antioxidants)
RN  - 0 (Cholinergic Agents)
SB  - IM
MH  - Humans
MH  - *Dementia, Vascular/drug therapy
MH  - Vascular Endothelial Growth Factor A
MH  - NF-kappa B/metabolism
MH  - Antioxidants
MH  - *Brain Ischemia
MH  - Cholinergic Agents
OTO - NOTNLM
OT  - mechanism of action
OT  - puerarin
OT  - research progress
OT  - vascular dementia
EDAT- 2023/12/20 06:41
MHDA- 2023/12/21 06:42
CRDT- 2023/12/19 20:45
PHST- 2023/12/21 06:42 [medline]
PHST- 2023/12/20 06:41 [pubmed]
PHST- 2023/12/19 20:45 [entrez]
AID - 10.19540/j.cnki.cjcmm.20230718.401 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):5993-6002. doi: 
      10.19540/j.cnki.cjcmm.20230718.401.